Securities Class Action

SAN FRANCISCO – A federal judge on Thursday dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.

%d bloggers like this: